{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Period+B&page=65",
    "query": {
      "intervention": "Period B",
      "page": 65
    },
    "page_size": 10
  },
  "pagination": {
    "page": 65,
    "page_size": 10,
    "total_count": 1575,
    "total_pages": 158,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Period+B&page=66&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Period+B&page=64&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-12T09:46:21.834Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07837869",
      "title": "PACE: Prostacyclin AntiCoagulation in ECMO",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "ECMO"
      ],
      "interventions": [
        {
          "name": "Dose-escalation study of epoprostenol as adjunct anticoagulation in ECMO",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Garrett Keim",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Days",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "0 Days to 17 Years"
      },
      "enrollment_count": 44,
      "start_date": "2026-11",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2026-11-10",
      "last_synced_at": "2026-11-12T09:46:21.834Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07837869"
    },
    {
      "nct_id": "NCT01992874",
      "title": "Relative Bioavailability of Pimasertib in Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "Pimasertib Capsule (Part A)",
          "type": "DRUG"
        },
        {
          "name": "Pimasertib Tablet (Part A)",
          "type": "DRUG"
        },
        {
          "name": "Pimasertib Capsule (Part B and trial extension phase)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 38,
      "start_date": "2013-11-30",
      "completion_date": "2015-02-28",
      "has_results": true,
      "last_update_posted_date": "2017-08-15",
      "last_synced_at": "2026-11-12T09:46:21.834Z",
      "location_count": 1,
      "location_summary": "Rockland, Massachusetts",
      "locations": [
        {
          "city": "Rockland",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01992874"
    },
    {
      "nct_id": "NCT05957913",
      "title": "Effects of Antiviral Therapies on Epstein-Barr Virus Replication",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Truvada (tenofovir/emtricitabine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2023-06-05",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-11-12T09:46:21.834Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05957913"
    },
    {
      "nct_id": "NCT02220218",
      "title": "Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC)",
          "type": "DRUG"
        },
        {
          "name": "Canagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Metformin IR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 2,
      "start_date": "2014-08",
      "completion_date": "2014-10",
      "has_results": false,
      "last_update_posted_date": "2014-11-19",
      "last_synced_at": "2026-11-12T09:46:21.834Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02220218"
    },
    {
      "nct_id": "NCT06550076",
      "title": "A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "TAK-279",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2099,
      "start_date": "2024-09-04",
      "completion_date": "2029-08-05",
      "has_results": false,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-11-12T09:46:21.834Z",
      "location_count": 74,
      "location_summary": "Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 62 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06550076"
    },
    {
      "nct_id": "NCT01332513",
      "title": "An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "Investigational Medicinal Product (MR1)",
          "type": "DRUG"
        },
        {
          "name": "Investigational Medicinal Product (MR2)",
          "type": "DRUG"
        },
        {
          "name": "Investigational Medicinal Product (MR3)",
          "type": "DRUG"
        },
        {
          "name": "Investigational Medicinal Product (MR4)",
          "type": "DRUG"
        },
        {
          "name": "Investigational Medicinal Product (MR5)",
          "type": "DRUG"
        },
        {
          "name": "Investigational Medicinal Product (IR)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 36,
      "start_date": "2011-02-10",
      "completion_date": "2011-05-23",
      "has_results": false,
      "last_update_posted_date": "2018-06-19",
      "last_synced_at": "2026-11-12T09:46:21.834Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01332513"
    },
    {
      "nct_id": "NCT07219615",
      "title": "A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Spontaneous Urticaria"
      ],
      "interventions": [
        {
          "name": "Ritlecitinib 50 mg",
          "type": "DRUG"
        },
        {
          "name": "Ritlecitinib 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo - 50 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo - 100 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2025-10-30",
      "completion_date": "2027-04-23",
      "has_results": false,
      "last_update_posted_date": "2026-10-26",
      "last_synced_at": "2026-11-12T09:46:21.834Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 16 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07219615"
    },
    {
      "nct_id": "NCT06099782",
      "title": "A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Renal Cell Carcinoma",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab (+) Berahyaluronidase alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 147,
      "start_date": "2023-12-26",
      "completion_date": "2027-02-15",
      "has_results": true,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-11-12T09:46:21.834Z",
      "location_count": 8,
      "location_summary": "Alexander City, Alabama • Anchorage, Alaska • Springdale, Arkansas + 5 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06099782"
    },
    {
      "nct_id": "NCT02383368",
      "title": "A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Refractory Solid Tumors",
        "Advanced Cancer"
      ],
      "interventions": [
        {
          "name": "ASP4132",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2015-03-23",
      "completion_date": "2018-04-27",
      "has_results": false,
      "last_update_posted_date": "2024-10-31",
      "last_synced_at": "2026-11-12T09:46:21.834Z",
      "location_count": 5,
      "location_summary": "New Haven, Connecticut • Chicago, Illinois • Rochester, Minnesota + 2 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02383368"
    },
    {
      "nct_id": "NCT04505397",
      "title": "Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "SKL24741",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SK Life Science, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 111,
      "start_date": "2020-02-13",
      "completion_date": "2022-10-27",
      "has_results": false,
      "last_update_posted_date": "2023-12-21",
      "last_synced_at": "2026-11-12T09:46:21.834Z",
      "location_count": 1,
      "location_summary": "West Bend, Wisconsin",
      "locations": [
        {
          "city": "West Bend",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04505397"
    }
  ]
}